Genelux Co. (NASDAQ:GNLX) Insider Sells $10,517.32 in Stock

Genelux Co. (NASDAQ:GNLXGet Free Report) insider Caroline Jewett sold 4,961 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $2.12, for a total value of $10,517.32. Following the completion of the sale, the insider now directly owns 16,174 shares of the company’s stock, valued at approximately $34,288.88. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Genelux Price Performance

GNLX traded up $0.16 during midday trading on Monday, reaching $2.14. 855,088 shares of the company’s stock traded hands, compared to its average volume of 200,740. Genelux Co. has a 52 week low of $1.71 and a 52 week high of $35.15. The firm has a fifty day moving average of $2.91 and a two-hundred day moving average of $6.52. The stock has a market capitalization of $73.51 million, a price-to-earnings ratio of -2.21 and a beta of -1.58.

Genelux (NASDAQ:GNLXGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.08). The business had revenue of $0.01 million during the quarter. Sell-side analysts forecast that Genelux Co. will post -0.86 EPS for the current year.

Institutional Trading of Genelux

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Genelux by 1,660.1% during the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after purchasing an additional 925,258 shares during the last quarter. Woodward Diversified Capital LLC boosted its stake in Genelux by 2,326.2% during the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock valued at $15,163,000 after purchasing an additional 1,037,663 shares during the last quarter. Advisor Resource Council purchased a new stake in Genelux during the 4th quarter valued at $233,000. Whittier Trust Co. of Nevada Inc. purchased a new stake in Genelux during the 4th quarter valued at $100,000. Finally, Apollon Wealth Management LLC purchased a new stake in Genelux during the 4th quarter valued at $196,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on GNLX shares. Benchmark lowered their price target on Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a research report on Friday, May 31st. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Genelux in a research report on Monday, May 13th.

Get Our Latest Research Report on Genelux

Genelux Company Profile

(Get Free Report)

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

Further Reading

Insider Buying and Selling by Quarter for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.